Liangfang Shen

机构：Central South University, Xiangya Hospital Central South University · ORCID：0000-0001-9474-6329

发表论文 52 篇 · 总被引 1525 次 · h-index 17

代表论文

• Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial (2021 · The Lancet Oncology · 被引 463)
• Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial (2021 · The Lancet · 被引 242)
• Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203) (2021 · Frontiers in Oncology · 被引 68)
• First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial (2021 · European Journal of Cancer · 被引 63)
• Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study (2022 · The Lancet Regional Health - Western Pacific · 被引 23)
• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 20)